Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Exicure, Inc. Reports Third Quarter 2025 Financial Results
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Exicure, Inc. Reports Second Quarter 2025 Financial Results
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
Exicure, Inc. Reports First Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.